stockrowBioCryst Pharmaceuticals, Inc. (BCRX) vs Xeris Biopharma Holdings, Inc. (XERS)
- BioCryst Pharmaceuticals, Inc. BCRX 7.55 −8.37%
- Xeris Biopharma Holdings, Inc. XERS 12.95 +23.80%
BioCryst Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $2.4B against $2.0B — 1.2× the size. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 60.3% against 38.4%. Xeris Biopharma Holdings, Inc. has the higher net margin (−1.76% vs −37.4%) and the higher return on invested capital (27.2% vs 0.00%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 13 and Xeris Biopharma Holdings, Inc. on 5.
Valuation
Profitability
| Metric | BCRX | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.89% | 87.38% | 53.51% |
| Operating margin | (30.10%) | 12.70% | 0.00% |
| Net margin | (37.41%) | (1.76%) | (2.45%) |
| Free cash flow margin | 38.11% | 20.00% | 0.00% |
| Return on equity | 91.60% | (27.11%) | (0.80%) |
| Return on assets | (69.33%) | (1.64%) | (1.67%) |
| Return on invested capital | 0.00% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack